Program
salanersen
Also written as “Salanersen” and “BIIB115”.
Its studies are mostly in Muscular Atrophy, Spinal, led by Biogen.
Furthest: phase 3, since Oct 24, 20254 company-led studies, 4 open or runningNext primary completion: Jun 23, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogen | 44 open or running | phase 3since Oct 24, 2025 | Oct 7, 2022 | Jun 23, 2028phase 3 · NCT07444476 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 7, 2022First study: phase 1 study in Muscular Atrophy, SpinalFirst studyNCT05575011 · 62 enrolled · Belgium, Canada, France and more
- Oct 24, 2025Phase 3 study in Muscular Atrophy, SpinalNCT07221669 · 30 planned · United States, Australia, Brazil and more
- Feb 26, 20262 phase 3 studies in Muscular Atrophy, SpinalNCT07444476, NCT07444450
Ahead
- Jun 23, 2028Primary completion: phase 3 study in Muscular Atrophy, SpinalNCT07444476
- Nov 28, 2028Primary completion: phase 3 study in Muscular Atrophy, SpinalNCT07221669
- Jul 27, 2029Primary completion: phase 3 study in Muscular Atrophy, SpinalNCT07444450
- Nov 14, 2031Primary completion: phase 1 study in Muscular Atrophy, SpinalNCT05575011
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07444476Muscular Atrophy, Spinal · United States, China, Japan and more | 3 | Recruiting | Jun 23, 2028 | 90 |
| NCT07444450Muscular Atrophy, Spinal · United States | 3 | Recruiting | Jul 27, 2029 | 42 |
| NCT07221669Muscular Atrophy, Spinal · United States, Australia, Brazil and more | 3 | Recruiting | Nov 28, 2028 | 30 |
| NCT05575011Muscular Atrophy, Spinal · Belgium, Canada, France and more | 1 | Active, not recruiting | Nov 14, 2031 | 62 |
How it is read
Names in the registry
- “Salanersen”, 3 entries
- “BIIB115”, 1 entry
Codes read as this program: BIIB115.
Conditions, from the studies’ own filings
- Muscular Atrophy, Spinal, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.